Revolution Medicines Inc reports results for the quarter ended March 31 - Earnings Summary

• Revolution Medicines Inc RVMD.OQ reported a quarterly adjusted loss of $1.13​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -70 cents. The mean expectation of eleven analysts for the quarter was for a loss of $1.09 per share. Wall Street expected results to range from $-1.23 to -91 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Revolution Medicines Inc's reported EPS for the quarter was a loss of $1.13​.

• The company reported a quarterly loss of $213.42 million.

• Revolution Medicines Inc shares had risen by 5.9% this quarter and lost 14.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

• Wall Street's median 12-month price target for Revolution Medicines Inc is $72.00

This summary was machine generated from LSEG data May 7 at 09:06 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)